279 related articles for article (PubMed ID: 32305010)
1. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
3. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
4. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.
Jones L; Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2022 Nov; 29(11):8686-8692. PubMed ID: 36421338
[TBL] [Abstract][Full Text] [Related]
5. Model-based simulation to support the extended dosing regimens of atezolizumab.
Chou CH; Hsu LF
Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
[TBL] [Abstract][Full Text] [Related]
6. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
[TBL] [Abstract][Full Text] [Related]
7. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø
Ann Oncol; 2016 Jul; 27(7):1291-8. PubMed ID: 27117531
[TBL] [Abstract][Full Text] [Related]
8. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
[TBL] [Abstract][Full Text] [Related]
9. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
Peer CJ; Schmidt KT; Arisa O; Richardson WJ; Paydary K; Goldstein DA; Gulley JL; Figg WD; Ratain MJ
J Clin Pharmacol; 2023 Jun; 63(6):672-680. PubMed ID: 36624662
[TBL] [Abstract][Full Text] [Related]
10. A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab.
Rowe M; Eastlake L; Norris T; Farley T; Talbot T
J Immunother; 2021 May; 44(4):175-178. PubMed ID: 33492031
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma.
Mehta I; Dayimu A; Kumar S; Boobier C; Oladipo O; Burke D; Olson-Brown A; Yesildag P; Nobes J; Brown S; Booth C; Wheater M; Muller D; Fountain V; Ford L; Board R; McGurk L; Twelves S; Demiris N; Corrie P
Eur J Cancer; 2023 Nov; 194():113344. PubMed ID: 37804771
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
Dubé-Pelletier M; Labbé C; Côté J; Pelletier-St-Pierre AA
Oncologist; 2023 Nov; 28(11):969-977. PubMed ID: 37364568
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
Shimizu T; Seto T; Hirai F; Takenoyama M; Nosaki K; Tsurutani J; Kaneda H; Iwasa T; Kawakami H; Noguchi K; Shimamoto T; Nakagawa K
Invest New Drugs; 2016 Jun; 34(3):347-54. PubMed ID: 27000274
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
17. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Hamid O; Robert C; Ribas A; Hodi FS; Walpole E; Daud A; Arance AS; Brown E; Hoeller C; Mortier L; Schachter J; Long J; Ebbinghaus S; Ibrahim N; Butler M
Br J Cancer; 2018 Sep; 119(6):670-674. PubMed ID: 30202085
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
20. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
